Intuitive Surgical (NASDAQ:ISRG) Director Sells $4,573,400.00 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Gary Guthart sold 10,000 shares of Intuitive Surgical stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $457.34, for a total value of $4,573,400.00. Following the completion of the sale, the director owned 1,194,530 shares of the company’s stock, valued at approximately $546,306,350.20. The trade was a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $16.34 during mid-day trading on Thursday, hitting $465.76. The company’s stock had a trading volume of 2,805,688 shares, compared to its average volume of 2,446,590. The stock has a market cap of $161.45 billion, a price-to-earnings ratio of 56.53, a price-to-earnings-growth ratio of 3.04 and a beta of 1.45. The company’s fifty day simple moving average is $406.25 and its 200-day simple moving average is $432.60. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The company had revenue of $3.05 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same quarter in the prior year, the business posted $2.40 EPS. The firm’s quarterly revenue was up 21.7% on a year-over-year basis. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 9.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ISRG. Mizuho decreased their price objective on shares of Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating for the company in a report on Wednesday, October 21st. Leerink Partners set a $503.00 price objective on shares of Intuitive Surgical and gave the company an “outperform” rating in a research report on Wednesday, October 21st. Royal Bank Of Canada dropped their price objective on Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 21st. Barclays reiterated an “overweight” rating and set a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a report on Wednesday, October 21st. Finally, Stifel Nicolaus decreased their target price on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $493.54.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. North Point Portfolio Managers Corp OH bought a new position in Intuitive Surgical during the third quarter worth about $27,000. John Boyer Inc. bought a new stake in Intuitive Surgical in the third quarter valued at approximately $27,000. Compass Wealth Management LLC acquired a new stake in shares of Intuitive Surgical in the third quarter valued at approximately $29,000. Main Street Group LTD bought a new position in shares of Intuitive Surgical during the 1st quarter worth approximately $30,000. Finally, Compass Financial Management LLC bought a new position in shares of Intuitive Surgical during the 2nd quarter worth approximately $30,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.